Abstract
Although immunotherapy has proved to be effective in a variety of cancer subtypes, the role of immune checkpoint inhibition in the treatment of prostate cancer remains unclear. Here we review results from the latest clinical trials and discuss data suggesting that certain genetic mutations may confer increased sensitivity to immune checkpoint blockade.
Keywords:
immune checkpoint inhibitors; immunotherapy; prostate cancer.
Copyright © 2020 Elsevier Inc. All rights reserved.
Publication types
-
Research Support, N.I.H., Extramural
MeSH terms
-
Adenocarcinoma / drug therapy
-
Adenocarcinoma / therapy*
-
Antineoplastic Agents, Immunological / administration & dosage
-
Antineoplastic Combined Chemotherapy Protocols / therapeutic use
-
Benzamides / administration & dosage
-
Clinical Trials as Topic
-
Combined Modality Therapy
-
Docetaxel / administration & dosage
-
Humans
-
Immune Checkpoint Inhibitors / administration & dosage
-
Immune Checkpoint Inhibitors / therapeutic use*
-
Immunotherapy*
-
Male
-
Molecular Targeted Therapy
-
Neoplasm Proteins / antagonists & inhibitors
-
Nitriles / administration & dosage
-
Phenylthiohydantoin / administration & dosage
-
Phthalazines / administration & dosage
-
Piperazines / administration & dosage
-
Prednisone / administration & dosage
-
Programmed Cell Death 1 Receptor / antagonists & inhibitors
-
Prostatic Neoplasms / drug therapy
-
Prostatic Neoplasms / therapy*
Substances
-
Antineoplastic Agents, Immunological
-
Benzamides
-
Immune Checkpoint Inhibitors
-
Neoplasm Proteins
-
Nitriles
-
PDCD1 protein, human
-
Phthalazines
-
Piperazines
-
Programmed Cell Death 1 Receptor
-
Docetaxel
-
Phenylthiohydantoin
-
enzalutamide
-
Prednisone
-
olaparib